Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04614168
Other study ID # AC19163
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 26, 2021
Est. completion date December 26, 2025

Study information

Verified date April 2024
Source University of Edinburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almost all people who have had type 1 diabetes for 5 years have a defect in secretion of the hormone Glucagon. This hormone is involved in the body's response to low blood glucose (hypoglycaemia). It works by releasing glucose stores from the liver to bring the blood glucose back to normal. This defect therefore increases the risk of severe hypoglycaemia. The reason for this Glucagon defect in people with Type 1 diabetes is currently unknown. This study aims to look at the Glucagon response to hypoglycaemia in 24 people with type 1 diabetes to ascertain whether tight blood glucose control over a period of time improves this response. The investigators aim to achieve good blood glucose control using new generation Automated Insulin Delivery systems (AIDs). This system is made of: an insulin pump, a continuous glucose monitor (CGM) and an algorithm that allows adjustment of insulin delivery based on the blood glucose readings from the CGM. This is the most up to date technology that there is in the management of type 1 diabetes. However, people using this technology often still have problems with high blood glucose after eating. To ensure a very good blood glucose control participants will also follow a low carbohydrate diet to prevent this blood glucose rise after meals. The Glucagon response to low blood glucose will be measured at zero and eight months using the hyperinsulinaemic hypoglycaemic clamp technique.


Description:

This is a feasibility pilot study involving 24 participants with type 1 diabetes. Participants will be recruited from the local type 1 diabetes clinic and insulin pump waiting list. Each participant will enter the trial for a period of 8 months. The investigators aim to test if maximising time in glycaemic range (blood glucose 3.9-10 mmol/L) will restore the glucagon response to insulin-induced hypoglycaemia. After signing informed consent participants will be screened for eligibility against the inclusion and exclusion criteria. Those who are eligible will have an initial 20-day period of baseline blood glucose data collection. This will be achieved using a blinded continuous glucose monitoring (CGM) device. Participants will continue on their pre-trial diabetes care during this period and will be required to monitor their own blood glucose as normal. The participants will be split into two groups using stratified sampling to match for: age, gender and BMI. Group 1 will be the control group. Participants in this group will continue on standard diabetes care for the duration of the trial. Participants will be required to undertake two further periods of blinded CGM monitoring at 4 and 8 months. Group 2 will be the intervention group. Participants in this group will be placed on the automated insulin delivery (AID) system and asked to follow a low carbohydrate diet of 30-40g of carbohydrate per main meal portion. The AID system will consist of: a Tandem t:slim X2 insulin pump with control IQ technology and a Dexcom G6 continuous glucose monitor. After receiving training on the use of the devices these participants will enter a 2 week study run-in period to become accustomed to the devices and so that device settings can be optimised. As a safety measure these participants will be asked to measure blood ketones at least once daily throughout the trial. Study staff will monitor the data from the participants study devices throughout the trial and adjust settings as required to maximise time in glycaemic range. At the beginning and end of the trial all participants will undergo a hyperinsulinaemic hypoglycaemic clamp study to measure their counterregulatory hormone response to hypoglycaemic. Participants will also undergo cognitive tests and assessment of hypoglycaemic awareness during each clamp study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 17
Est. completion date December 26, 2025
Est. primary completion date December 26, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Participants with Type 1 diabetes with C-peptide levels less than 200pmol/L. - Type 1 diabetes for 5 years or more. - HbA1c greater than or equal to 53 mol/mol. - Normal renal function. - Normal thyroid function. - Gold Score 4-7 (indicating impaired awareness of hypoglycaemia) - Willingness to monitor blood ketones daily. - Use of freestyle libre device is permitted at study entry and may be continued in participants in group 1 Exclusion Criteria: - Current use of a non-approved closed loop / AID system or those on a predictive low glucose suspend insulin pump. - Proliferative retinopathy - Regular use of real time CGM in the preceding 3 months. - History of Diabetic ketoacidosis in the preceding 6 months. - Severe hypoglycaemic episode requiring external assistance in the preceding 6 months. - Inability to safely use technology used in this study (e.g. impaired vision, memory or dexterity that prevents safe operation of CGM or insulin pump.) - Inability to support the technology requirements for the study (e.g. unable to upload study device at home) - History of Haemophilia, Cystic Fibrosis, pancreatic disease or complete pancreatectomy, ischaemic heart disease, epilepsy or hypoglycaemia induced seizure - History of severe reaction or allergy to adhesive necessary to this study. - Unable to adhere to study timetable. - Unable to give informed consent. - Pregnancy. We will perform a pregnancy test on all eligible participants at baseline. - Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas. These may lower insulin requirements and predispose to diabetic ketoacidosis. - Concurrent use of medication that may affect blood glucose such as SSRIs - A condition, which in the opinion of the investigator, would put the patient or study at risk - HbA1c greater than or equal to 75 mmol/mol

Study Design


Intervention

Procedure:
Stepped hyperinsulinaemic-hypoglycaemic clamp study
Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
Device:
Insulin pump
Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
Continuous glucose monitor
Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
Other:
Low carbohydrate diet
30-40g of carbohydrate per main meal portion.
Device:
Blinded continuous glucose monitor
Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
Procedure:
Stable isotope studies- D2 Glucose and D5 Glycerol
These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.

Locations

Country Name City State
United Kingdom Edinburgh Royal Infirmary/University of Edinburgh Edinburgh

Sponsors (5)

Lead Sponsor Collaborator
University of Edinburgh DexCom, Inc., NHS Lothian, Tandem Diabetes Care, Inc., The Leona M. and Harry B. Helmsley Charitable Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end 8 months
Secondary Time in glycaemic range (3.9-10mmol/L) Percentage time spent in target glycaemic range. 8 months
Secondary Time spent below the target glycaemic range (<3.9mmol/L) Percentage of time spent below the target glycaemic range 8 months
Secondary Time spent above the target glycaemic range (>10mmol/L) Percentage of time spent above the target glycaemic range 8 months
Secondary The change in plasma cortisol (nmol/L) levels measured during normoglycaemic and hypoglycaemia Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end 8 months
Secondary The change in plasma adrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end 8 months
Secondary The change in plasma noradrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end 8 months
Secondary Endogenous glucose production Measured with stable isotope studies using D2 glucose and D5 glycerol 8 months
Secondary HbA1c Difference between baseline and study end 8 months
Secondary Change in quality of life at trial entry and end. Measured using the EQ5D-5L- a quality of life questionnaire comprising of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension consists of five levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant ticks the box most relevant to them at the time of taking the questionnaire. This response is converted into a 1 digit number and the 5 numbers from a domain can be combined to describe the participant's health state. This questionnaire will be completed at trial entry and then at trial end. 8 months
Secondary Change in emotional distress related to diabetes at trial entry and end. Diabetes Distress Scale (DDS-1)- a 28-item self-reporting scale. Each item can be scored from 1 (not a problem) to 6 (a very serious problem). This questionnaire will be completed at study entry and study end. 8 months
Secondary Attitude to diabetes technologies Measured using the Diabetes Technology Questionnaire- a 30 item questionnaire. The participant ranks each item from Very Much (1) to Not at all (5). Participants will complete this questionnaire at study entry and study end. Also assessed using the Diabetes Technology Attitudes Survey- a 5 item questionnaire. The participant ranks each item from Strongly Disagree (1) to Strongly Agree (5). 8 months
Secondary Change in fear of hypoglycaemic Measured using the Hypoglycaemia Fear Survey (HFS)- this survey consists of two subscales- Behaviour and Worry. There are 28 items in the survey that the participant ranks from Never (0) to Almost Always (4). Participants will complete this questionnaire at study entry and study end. 8 months
Secondary Change in confidence of managing hypoglycaemia Measured using the Hypoglycaemic Confidence Scale- this is a 9 item scale. The participant rates each item from Not Confident at All to Very Confident. Participants will complete this questionnaire at study entry and study end. 8 months
Secondary Hypoglycaemia awareness Measured during each clamp study using the Edinburgh Hypoglycaemic Scale- this is a 17 item scale of symptoms of hypoglycaemia. The participant ranks on a scale from Not at all (1) to A Great Deal (7) whether they are experiencing each symptom at the time of the questionnaire being completed. 8 months
Secondary Trial Making Test Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end. 8 months
Secondary Digit Span Test Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end. 8 months
Secondary Digit Symbol Substitution Test Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end. 8 months
Secondary Four Choice Reaction Time Test Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end. 8 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2